Literature DB >> 33425881

Current Trends of Targeted Drug Delivery for Oral Cancer Therapy.

Mingming Zhang1, Jianqin Liang2, Yanyu Yang3, Huize Liang1, Huaping Jia1, Dawei Li4.   

Abstract

Oral cancer is an aggressive tumor that invades the local tissue and can cause metastasis and high mortality. Conventional treatment strategies, e.g., surgery, chemotherapy, and radiation therapy alone or in combinations, possess innegligible issues, and significant side and adverse effects for the clinical applications. Currently, targeting drug delivery is emerging as an effective approach for oral delivery of different therapeutics. Herein we provide a state-of-the-art review on the current progress of targeting drug delivery for oral cancer therapy. Variously oral delivery systems including polymeric/inorganic nanoparticles, liposomes, cyclodextrins, nanolipids, and hydrogels-based forms are emphasized and discussed, and biomimetic systems with respect to oral delivery like therapeutic vitamin, exosomes, proteins, and virus-like particles are also described with emphasis on the cancer treatment. A future perspective is also provided to highlight the existing challenges and possible resolution toward clinical translation of current oral cancer therapies.
Copyright © 2020 Zhang, Liang, Yang, Liang, Jia and Li.

Entities:  

Keywords:  OSCC (oral squamous cell carcinoma); drug delivery; nanoparticles; nanotechnology; oral cancer

Year:  2020        PMID: 33425881      PMCID: PMC7793972          DOI: 10.3389/fbioe.2020.618931

Source DB:  PubMed          Journal:  Front Bioeng Biotechnol        ISSN: 2296-4185


  6 in total

1.  Targeting lncRNA PSMA3-AS1, a Prognostic Marker, Suppresses Malignant Progression of Oral Squamous Cell Carcinoma.

Authors:  Xinghua Cao; Kefeng Luan; Jie Yang; Yundong Huang
Journal:  Dis Markers       Date:  2021-08-19       Impact factor: 3.434

2.  Macrophage migration inhibitory factor facilitates the therapeutic efficacy of mesenchymal stem cells derived exosomes in acute myocardial infarction through upregulating miR-133a-3p.

Authors:  Wenwu Zhu; Ling Sun; Pengcheng Zhao; Yaowu Liu; Jian Zhang; Yuelin Zhang; Yimei Hong; Yeqian Zhu; Yao Lu; Wei Zhao; Xinguang Chen; Fengxiang Zhang
Journal:  J Nanobiotechnology       Date:  2021-02-27       Impact factor: 10.435

Review 3.  Drug delivery systems for oral disease applications.

Authors:  Yue Zhang; Ruining Jiang; Lei Lei; Yingming Yang; Tao Hu
Journal:  J Appl Oral Sci       Date:  2022-03-09       Impact factor: 2.698

4.  A nanoengineered topical transmucosal cisplatin delivery system induces anti-tumor response in animal models and patients with oral cancer.

Authors:  Manijeh Goldberg; Aaron Manzi; Peter Conway; Stefanie Cantin; Vasudha Mishra; Alka Singh; Alexander T Pearson; Eric R Goldberg; Sam Goldberger; Benjamin Flaum; Rifat Hasina; Nyall R London; Gary L Gallia; Chetan Bettegowda; Sonya E O'Neill; Erkin Aydin; Alex Zhavoronkov; Anxo Vidal; Atenea Soto; Maria Jose Alonso; Ari J Rosenberg; Mark W Lingen; Anil D'Cruz; Nishant Agrawal; Evgeny Izumchenko
Journal:  Nat Commun       Date:  2022-08-17       Impact factor: 17.694

Review 5.  Liquid Biopsy and Circulating Biomarkers for the Diagnosis of Precancerous and Cancerous Oral Lesions.

Authors:  Giuseppe Gattuso; Salvatore Crimi; Alessandro Lavoro; Roberta Rizzo; Giorgia Musumarra; Simona Gallo; Flavia Facciponte; Sabrina Paratore; Angela Russo; Roberto Bordonaro; Gaetano Isola; Alberto Bianchi; Massimo Libra; Luca Falzone
Journal:  Noncoding RNA       Date:  2022-08-10

6.  lncRNA TSPEAR-AS2, a Novel Prognostic Biomarker, Promotes Oral Squamous Cell Carcinoma Progression by Upregulating PPM1A via Sponging miR-487a-3p.

Authors:  Yi-Chao Xia; Jun Cao; Jing Yang; Ying Zhang; Yong-Sheng Li
Journal:  Dis Markers       Date:  2021-07-17       Impact factor: 3.434

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.